Effects of statins on the c-reactive protein of dyslipidemic patients in the university of Port-Harcourt teaching hospital

Stella-Maris C. Egboh, Iyeopu M. Siminialayi


Background: Dyslipidemia is a modifiable cardiovascular risk factor associated with systemic inflammation and can be assessed with a recognized bio-marker known as C-reactive protein.

Methods: This was a cohort study carried out over a period of 9 months, where subjects who had abnormality in any of the fasting lipid parameters were recruited into the study, all the subjects had their C-reactive protein assessed, the test subjects were commenced on statins while the control subjects were not on statins and they were all followed up for a period of 3 months after which C-reactive protein was re-assessed.

Results: Total 320 subjects were recruited, comprising of 160 test subjects and 160 control subjects. The mean age± SD of the test subjects was 57.02±12.45, while the control subjects had 51.86±13.27 as their mean age± SD. Statins had a significant effect on the reduction of C-reactive protein (p=0.001). Although, there was no correlation between the dosages of statins and its effect on C-reactive protein.

Conclusions: Statins were found to have anti-inflammatory effects, although there was no significant correlation between the dosages of statins and their effect on c-reactive protein.


Anti-inflammatory, C-reactive protein, Statins

Full Text:



Houston MC, Fazio S, Chilton FH, Wise DE, Jones KB, Barringer TA, et al. Nonpharmacologic treatment of dyslipidemia. Prog Cardiovas Dis. 2009 Sep 1;52(2):61-94.

Clark M, Finkel R, Rey J, Whalen K. Lippincott’s Illustrated Reviews: Pharmacology. Lippincott Williams and Wilkins, Baltimore. 5th Edition; 2012:455-560.

Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon III RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 Jan 28;107(3):499-511.

Expert Panel on Detection E. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486.

Qi L, Ding X, Tang W, Li Q, Mao D, Wang Y. Prevalence and risk factors associated with dyslipidemia in Chongqing, China. Int J Environ Res Public Health. 2015 Oct 26;12(10):13455-65.

Doupa D, Mbengue AS, Diallo FA, Jobe M, Ndiaye A, Kane A, Diatta A, Touré M. Lipid profile frequency and the prevalence of dyslipidaemia from biochemical tests at Saint Louis University Hospital in Senegal. Pan African Med J. 2014;17(1).

Okafor CI, Fasanmade OA, Oke DA. Pattern of dyslipidaemia among Nigerians with type 2 diabetes mellitus. Nigerian J Clin Practice. 2008;11(1):25-31.

Okaka EI, Eiya BO. Prevalence and pattern of dyslipidemia in a rural community in Southern Nigeria. African J Med Health Sci. 2013 Jul 1;12(2):82.

Odenigbo CU, Oguejiofor OC, Odenigbo UM, Ibeh CC, Ajaero CN, Odike MA. Prevalence of dyslipidaemia in apparently healthy professionals in Asaba, South South Nigeria. Nigerian J Clin Pract. 2008;11(4).

Ridker PM, Glynn RJ. Rosuvastatin in patients with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207.